Enzolytics Inc ENZC
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.00
- Bid/Ask
- $0.00 / $0.00
- Shares Outstanding
- 4.83B
- Market Cap
- $1.93M
- Volume/Avg
- 2M / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Enzolytics Inc is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. The company is committed to creating drugs for the good health of mankind. ENZC's flagship compound, ITV-1, is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 1
- Website
- https://www.enzolytics.com
Valuation
|
Metric
|
ENZC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ENZC
|
|---|---|
Quick Ratio | 0.01 |
Current Ratio | 0.06 |
Interest Coverage | −92.76 |
Quick Ratio
No chart available
Profitability
|
Metric
|
ENZC
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
No chart available
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|$#>B!<p | LOCK|%W^> | $128B | |||
| Moderna Inc
MRNA
| LOCK|tBk^^j? | LOCK|mB | $81B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|D?NNht< | LOCK|@SN%& | $75B | |||
| argenx SE ADR
ARGX
| LOCK|Z<&ZH! | LOCK|^wt | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|vzlxp?S | LOCK|Zy> | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|!Z%Ck^? | LOCK|F&@Pr | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|NW>#z!h | LOCK|#&&< | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|>$?LhT | LOCK|C>H | $25B | |||
| Incyte Corp
INCY
| LOCK|qSPXt>V | LOCK|^y | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|?#FN?LB | LOCK|!& | $15B |
United States